Real-World Evidence for Efficacy and Safety of Durvalumab Consolidation After Chemoradiotherapy in Patients With Unresectable Stage III NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR
J Thorac Oncol 2023 Apr 19;[EPub Ahead of Print], CK Park, HJ Oh, YC Kim, YH Kim, SJ Ahn, WG Jeong, JY Lee, JC Lee, CM Choi, W Ji, SY Song, J Choi, SY Lee, H Kim, SY Lee, J Park, SH Yoon, JH Joo, IJ OhFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.